Our attorneys have filed a mass tort lawsuit on behalf of sufferers who took the blood thinner Xarelto (rivaroxaban) and suffered severe bleeding events. Pharmaceutical businesses, like the makers of Xarelto, have a duty to make sure that their drugs are reasonably protected for use - and failure to do so may possibly be grounds for compensation. Our lawyers are operating difficult to obtain those hurt by the drug the compensation they may be entitled to.
Whilst bleeding is actually a common complication Related Homepag
with anticoagulants, it has been alleged that Xarelto is more hazardous than conventional blood thinners since no antidote exists to reverse its blood-thinning effects. This signifies that, in the event of an emergency, sufferers could be at threat for irreversible bleeding problems, which includes life-threatening internal and gastrointestinal hemorrhaging.
In the event you or even a loved 1 suffered a severe bleeding event after taking Xarelto, you may have legal recourse. For more data, make contact with us right now to possess your case reviewed, totally free of charge.
xarelto-compensation-photoThe plaintiffs in these lawsuits are in search of compensation from Bayer and Janssen for past and future health-related bills, lost wages, discomfort and suffering and, in instances of death, funeral costs. Additionally, they may be looking for punitive damages, that are normally awarded to punish the defendant and deter other firms from acting similarly.
Why Are Lawsuits Being Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is dangerous and defective. The plaintiffs claim that, unlike standard anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Due to the fact of this, the lawsuits claim, doctors have no effective means of stopping Xarelto users from bleeding within the occasion of an emergency. Plaintiffs in the lawsuits allege significant and fatal injuries, such as cerebral hemorrhaging and gastrointestinal
bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior in the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a secure anticoagulant option.
Doctors and healthcare staff were not properly made aware of methods to stabilize and treat a Xarelto user in the event of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to serious bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing harmful clotting.
Visit this page for far more information on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys inside the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.